MLS-101
Mineralys Therapeutics
['cardio']
today we presented positive data from the target-htn study at #acc23 #wccardio demonstrating clinically meaningful #bloodpressure reduction with lorundrostat. importantly, obesity was a predictor of an enhanced response. read our release to learn more: 
We're a private, clinical-stage biopharmaceutical company committed to developing a best-in-class, novel therapy for hypertension.